Gao Weiqi, Yan Ya, Guan Zhaobo, Zhang Jingmin, Chen Weihong
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, China.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Microbiol. 2024 Mar 26;15:1284402. doi: 10.3389/fmicb.2024.1284402. eCollection 2024.
The primary objective of this study is to investigate the mechanism by which TBC169 accelerates intestinal function recovery in patients who have undergone gynecological laparoscopic surgery, using metabolomics and gut microbiota analysis.
A total of 20 subjects were selected and randomly divided into two groups: the intervention group ( = 10) receiving TBC169 Tablets (6 pills, 1.05 × 10 CFU), and the control group ( = 10) receiving placebos (6 pills). After the initial postoperative defecation, fecal samples were collected from each subject to analyze their gut microbiota and metabolic profiles by high-throughput rRNA gene sequencing analysis and untargeted metabonomic.
There were no statistically significant differences observed in the α-diversity and β-diversity between the two groups; however, in the intervention group, there was a significant reduction in the relative abundance of at the genus level. Furthermore, the control group showed increased levels of and , whereas the intervention group exhibited elevated levels of . And administration of TBC169 led to variations in 2 metabolic pathways: D-glutamine and D-glutamate metabolism, and arginine biosynthesis.
This study demonstrated that consuming TBC169 after gynecological laparoscopic surgery might inhibit the proliferation of harmful ; mainly influence 2 pathways including D-glutamine and D-glutamate metabolism, and arginine biosynthesis; and regulate metabolites related to immunity and intestinal motility; which can help regulate immune function, maintain intestinal balance, promote intestinal peristalsis, and thus accelerate the recovery of intestinal function.
本研究的主要目的是利用代谢组学和肠道微生物群分析，探究TBC169加速妇科腹腔镜手术患者肠道功能恢复的机制。
共选取20名受试者，随机分为两组：干预组（n = 10）服用TBC169片（6片，1.05×10⁹CFU），对照组（n = 10）服用安慰剂（6片）。术后首次排便后，从每位受试者收集粪便样本，通过高通量rRNA基因测序分析和非靶向代谢组学分析其肠道微生物群和代谢谱。
两组之间的α多样性和β多样性无统计学显著差异；然而，在干预组中，属水平上的相对丰度显著降低。此外，对照组的[具体物质1]和[具体物质2]水平升高，而干预组的[具体物质3]水平升高。服用TBC169导致2条代谢途径发生变化：D-谷氨酰胺和D-谷氨酸代谢以及精氨酸生物合成。
本研究表明，妇科腹腔镜手术后服用TBC169可能抑制有害菌的增殖；主要影响D-谷氨酰胺和D-谷氨酸代谢以及精氨酸生物合成这2条途径；并调节与免疫和肠道蠕动相关的代谢物；这有助于调节免疫功能、维持肠道平衡、促进肠道蠕动，从而加速肠道功能的恢复。
